Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Company news centers on its off-the-shelf cell-therapy pipeline, including prulacabtagene leucel, or prula-cel, a CD20-targeted CAR gamma delta T cell therapy, and ADI-212, a PSMA-targeted candidate.
Recurring updates also cover clinical and regulatory disclosures, operating and financial results, biotechnology conference participation, inducement equity grants under Nasdaq rules, shareholder voting matters, Nasdaq listing compliance, and capital-structure actions involving common stock.
Adicet Bio (Nasdaq: ACET) reported completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in systemic lupus erythematosus (SLE) with or without lupus nephritis, with topline data expected in September 2026.
The planned analysis will include 22 SLE patients with at least 6 months of follow-up, including 13 with at least 12 months. Adicet expanded prula-cel administration into the outpatient setting after FDA alignment and is developing a potential registrational trial design. The FDA cleared the IND for ADI-212 in metastatic castration-resistant prostate cancer, with Phase 1 enrollment planned for 4Q 2026. The company is also advancing a diversified in vivo CAR-T portfolio, with the first candidate expected to enter clinical development in the second half of 2027.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta CAR T and in vivo CAR T therapies, reported an inducement stock option grant made on August 31, 2026 under Nasdaq Listing Rule 5635(c)(4). One new employee hired in August 2026 received non-qualified options to purchase 1,500 shares of common stock at an exercise price of $8.70 per share, equal to the Nasdaq closing price on August 31, 2026. One-fourth of the options will vest on the first anniversary of the employee’s start date, with the remaining three-fourths vesting in 36 substantially equal monthly installments over the following three years, subject to continued employment. The grant was made outside stockholder-approved equity plans under Adicet’s 2022 Inducement Plan and was approved by the independent compensation committee as a material inducement to employment.
Adicet Bio (Nasdaq: ACET) reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for ADI-212, an allogeneic gamma delta 1 CAR T cell therapy candidate for patients with metastatic castration-resistant prostate cancer (mCRPC). Phase 1 enrollment in mCRPC is expected to begin in the fourth quarter of 2026.
According to Adicet Bio, ADI-212 is a next-generation, gene-edited, off-the-shelf cell therapy targeting PSMA, engineered with membrane-tethered IL-12 armoring and CRISPR/Cas9-mediated disruption of MED12 to support tumor-specific recognition and multiple anti-tumor mechanisms in the tumor microenvironment.
Adicet Bio (Nasdaq: ACET) reported second quarter 2026 results and pipeline progress. For the quarter ended June 30, 2026, research and development expenses were $18.5 million, general and administrative expenses $3.9 million, and net loss $21.4 million, or $1.99 per basic and diluted share.
Cash, cash equivalents and short-term investments totaled $118.2 million, which the company expects will fund operations into the second half of 2027. Adicet plans a comprehensive Phase 1 update for prulacabtagene leucel (prula-cel) in LN and SLE in 3Q 2026, informed by productive FDA interactions on a potential pivotal LN trial. A regulatory filing for ADI-212 in mCRPC is expected in 3Q 2026, with Phase 1 enrollment anticipated in 4Q 2026, and an update on its in vivo CAR-T platform is planned for the second half of 2026. The company appointed Lloyd Klickstein, M.D., Ph.D. as Interim Chief Medical Officer.
Lipocine (NASDAQ: LPCN) appointed Michael J. Grissinger to its Board of Directors, effective August 3, 2026. The company develops therapeutics using a proprietary oral delivery technology platform.
Grissinger previously spent over two decades at Johnson & Johnson in senior roles leading worldwide pharmaceutical licensing, corporate development, and M&A, including heading Immunology business development and licensing. Earlier, he worked 12 years at Ciba-Geigy in finance, marketing, and business development. He currently serves on the boards of Aprea Therapeutics (Nasdaq: APRE) and Adicet Bio (Nasdaq: ACET), and advises several private biotech companies. According to Lipocine, his experience is expected to support advancement of its pipeline and partnership efforts.
Adicet Bio (Nasdaq: ACET) announced that President and CEO Chen Schor will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference, held August 11-13, 2026, in Boston.
The session is scheduled for Tuesday, August 11, 2026, at 10:30 a.m. ET, with a live audio webcast and 30-day replay available via the Investors section of Adicet Bio’s website.
Adicet Bio (Nasdaq: ACET) announced that President and CEO Chen Schor will join a fireside chat at the Jefferies Global Healthcare Conference in New York.
The session is scheduled for Thursday, June 4, 2026, at 7:35 a.m. ET, with a live webcast and 30-day replay via the company’s investor website.
Adicet Bio (Nasdaq: ACET) reported first quarter 2026 results and pipeline updates. Net loss was $20.2 million ($1.88 per share) versus $28.2 million a year ago. R&D fell to $17.5 million and G&A to $4.1 million. Cash and investments were $137.6 million, expected to fund operations into the second half of 2027.
Key programs include a mid-2026 Phase 1 update for prula-cel in at least 20 LN and SLE patients, potential pivotal start in 2H 2026, an RA Phase 1 trial, and planned 3Q 2026 regulatory filing for ADI-212 in mCRPC.
Adicet Bio (Nasdaq: ACET) reported Q4 and full‑year 2025 results and clinical progress on prula‑cel and ADI‑212. Key operational updates include FDA Fast Track designation for prula‑cel, FDA alignment enabling outpatient dosing for LN and SLE, strong enrollment momentum with clinical updates expected in 1H and 2H 2026, and a planned regulatory filing for ADI‑212 in 3Q/2026.
Financially, 2025 net loss was $116.8M, cash and short‑term investments were $158.5M at year‑end, and the company raised $74.8M net in October 2025; cash runway is expected into H2 2027.
Adicet Bio (Nasdaq: ACET) announced that Chen Schor, President and CEO, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 2:00 p.m. ET.
The presentation will be available via a live audio webcast on the company’s Investors website, with an archived replay accessible for 30 days after the event.